These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 2285650)

  • 1. Pathogenesis and treatment of Raynaud's phenomenon.
    Coffman JD
    Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():45-51. PubMed ID: 2285650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raynaud's phenomenon. An update.
    Coffman JD
    Hypertension; 1991 May; 17(5):593-602. PubMed ID: 2022404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of vasospastic attacks despite digital nerve block in Raynaud's disease and phenomenon.
    Freedman RR; Mayes MD; Sabharwal SC
    Circulation; 1989 Oct; 80(4):859-62. PubMed ID: 2791249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud's Phenomenon.
    Coffman JD
    Curr Treat Options Cardiovasc Med; 2000 Jun; 2(3):219-226. PubMed ID: 11096527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Raynaud's disease.
    Cooke JP; Marshall JM
    Vasc Med; 2005 Nov; 10(4):293-307. PubMed ID: 16444858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnosis and treatment of Raynaud's phenomenon.
    Porter JM; Snider RL; Bardana EJ; Rösch J; Eidemiller LR
    Surgery; 1975 Jan; 77(1):11-23. PubMed ID: 1078555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Cardiol; 1985 Jan; 55(3):154B-157B. PubMed ID: 3881908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease.
    Freedman RR; Baer RP; Mayes MD
    Circulation; 1995 Sep; 92(6):1448-51. PubMed ID: 7664425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding, assessing and treating Raynaud's phenomenon.
    Boin F; Wigley FM
    Curr Opin Rheumatol; 2005 Nov; 17(6):752-60. PubMed ID: 16224254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
    Coleiro B; Marshall SE; Denton CP; Howell K; Blann A; Welsh KI; Black CM
    Rheumatology (Oxford); 2001 Sep; 40(9):1038-43. PubMed ID: 11561116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin and Raynaud's phenomenon.
    Seibold JR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S95-8. PubMed ID: 2412070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cutaneous vasoconstrictor response to venous stasis is normal in subjects with primary Raynaud's disease.
    Edwards CM; Marshall JM; Pugh M
    Clin Auton Res; 1999 Oct; 9(5):255-62. PubMed ID: 10580877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational use of calcium-channel antagonists in Raynaud's phenomenon.
    Sturgill MG; Seibold JR
    Curr Opin Rheumatol; 1998 Nov; 10(6):584-8. PubMed ID: 9812220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local and central orthostatic sympathetic reflexes in Raynaud's phenomenon.
    Engelhart M; Kristensen JK
    Scand J Clin Lab Invest; 1991 Apr; 51(2):191-6. PubMed ID: 2042023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.